Iovance Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	71.43	263.5	164.07	1.19	-	-
Revenue Growth	129.63%	60.60%	13698.99%	-	-	-
Cost of Revenue	180.75	173.18	93.25	1.03	-	-
Gross Profit	-109.32	90.32	70.82	0.16	-	-
Selling, General & Admin	147.6	152.32	152.27	106.1	104.1	83.66
Depreciation & Amortization Expenses	-	35.94	37.6	21.42	-	-
Research & Development	288.23	300.27	276.23	333.19	294.78	259.04
Other Operating Expenses	-	5.14	-	-	-	-
Total Operating Expenses	435.83	493.67	466.1	460.72	398.88	342.7
Operating Income	-363.18	-403.36	-395.28	-460.56	-398.88	-342.7
Interest Income	8.42	10.31	20.27	13.04	2.99	0.45
Total Non-Operating Income (Expense)	8.42	10.31	20.27	13.04	2.99	0.45
Pretax Income	-354.76	-393.05	-375.01	-447.52	-395.89	-342.25
Provision for Income Taxes	-0.9	-2.07	-2.83	-3.48	-	-
Net Income	-353.86	-390.98	-372.18	-444.04	-395.89	-342.25
Net Income to Common	-353.86	-390.98	-372.18	-444.04	-395.89	-342.25
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	381	357	290	235	159	153
Shares Outstanding (Diluted)	381	357	290	235	159	153
Shares Change	25.35%	23.28%	23.28%	47.64%	3.82%	10.92%
EPS (Basic)	-0.95	-1.09	-1.28	-1.89	-2.49	-2.23
EPS (Diluted)	-0.95	-1.09	-1.28	-1.89	-2.49	-2.23
EPS Growth	-	-	-	-	-	-
Free Cash Flow	-305.02	-336.24	-364.05	-384.11	-313.18	-265.52
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	-0.80	-0.94	-1.26	-1.63	-1.97	-1.73
Gross Margin	-153.05%	34.28%	43.17%	13.12%	-	-
Operating Margin	-508.44%	-153.08%	-240.92%	-38735.00%	-	-
Profit Margin	-495.39%	-148.38%	-226.84%	-37345.40%	-	-
FCF Margin	-427.02%	-127.61%	-221.89%	-32305.30%	-	-
EBITDA	-316.59	-356.03	-347.21	-427.43	-377.74	-328.72
EBITDA Margin	-443.22%	-135.12%	-211.62%	-35948.90%	-	-
EBIT	-363.18	-403.36	-395.28	-460.56	-398.88	-342.7
EBIT Margin	-508.44%	-153.08%	-240.92%	-38735.00%	-	-
Effective Tax Rate	0.25%	0.53%	0.75%	0.78%	0.00%	0.00%

SEC Filings: 10-K · 10-Q